6609 Stock Overview
Researches, develops, manufacture, and sells neuro-interventional medical devices in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Shanghai HeartCare Medical Technology Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$21.40 |
| 52 Week High | HK$29.80 |
| 52 Week Low | HK$12.10 |
| Beta | 0.69 |
| 11 Month Change | 7.00% |
| 3 Month Change | 70.38% |
| 1 Year Change | -23.43% |
| 33 Year Change | -75.17% |
| 5 Year Change | n/a |
| Change since IPO | -83.41% |
Recent News & Updates
Even With A 42% Surge, Cautious Investors Are Not Rewarding Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) Performance Completely
Sep 27
Some Shareholders Feeling Restless Over Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) P/S Ratio
Aug 01Recent updates
Even With A 42% Surge, Cautious Investors Are Not Rewarding Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) Performance Completely
Sep 27Some Shareholders Feeling Restless Over Shanghai HeartCare Medical Technology Corporation Limited's (HKG:6609) P/S Ratio
Aug 01We're Not Very Worried About Shanghai HeartCare Medical Technology's (HKG:6609) Cash Burn Rate
Jan 23Shanghai HeartCare Medical Technology Corporation Limited (HKG:6609) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Aug 30Companies Like Shanghai HeartCare Medical Technology (HKG:6609) Are In A Position To Invest In Growth
Aug 09Companies Like Shanghai HeartCare Medical Technology (HKG:6609) Are In A Position To Invest In Growth
May 07We're Hopeful That Shanghai HeartCare Medical Technology (HKG:6609) Will Use Its Cash Wisely
Nov 29Shareholder Returns
| 6609 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | 7.1% | -3.5% | -0.6% |
| 1Y | -23.4% | -39.2% | 9.6% |
Return vs Industry: 6609 exceeded the Hong Kong Medical Equipment industry which returned -39.2% over the past year.
Return vs Market: 6609 underperformed the Hong Kong Market which returned 9.6% over the past year.
Price Volatility
| 6609 volatility | |
|---|---|
| 6609 Average Weekly Movement | 13.7% |
| Medical Equipment Industry Average Movement | 9.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 6609's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6609's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 341 | Guohui Wang | www.heartcare.com.cn |
Shanghai HeartCare Medical Technology Corporation Limited researches, develops, manufacture, and sells neuro-interventional medical devices in Mainland China. The company offers ischemic stroke thrombectomy devices, such as Captor thrombectomy device, and aspiration catheter and pump; intracranial stenosis treatment devices comprising intracranial drug-eluting balloon catheter and embolization protection system; hemorrhagic stroke treatment devices, including coil embolization assistant stent and flow diverter device; and ischemic stroke prevention devices, such as LAA occlude. It also provides vascular access devices comprising distal access catheter, microcatheter, balloon guiding catheter, vascular closure device, support catheter, neuro-interventional microcatheter, micro guidewire, microcatheter for coiling, microcatheter for flow diverter device, and navigation catheter.
Shanghai HeartCare Medical Technology Corporation Limited Fundamentals Summary
| 6609 fundamental statistics | |
|---|---|
| Market cap | HK$816.22m |
| Earnings (TTM) | -HK$48.12m |
| Revenue (TTM) | HK$269.92m |
3.0x
P/S Ratio-17.0x
P/E RatioIs 6609 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6609 income statement (TTM) | |
|---|---|
| Revenue | CN¥251.24m |
| Cost of Revenue | CN¥96.89m |
| Gross Profit | CN¥154.36m |
| Other Expenses | CN¥199.15m |
| Earnings | -CN¥44.79m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.17 |
| Gross Margin | 61.44% |
| Net Profit Margin | -17.83% |
| Debt/Equity Ratio | 0% |
How did 6609 perform over the long term?
See historical performance and comparison